The Effect of Brand, Thickness, and Abutment Substrate on the Masking Ability of Monolithic Zirconia Cera The goal of the present study was to determine the minimum thickness of monolithic zirconia required to achieve an acceptable masking ability and to examine how brand, thickness, and abutment substrate influenced that masking ability (∆E). Seventy-two A2-shade monolithic zirconia disc specimens in various thicknesses (1.0, 1.5, and 2.0 mm) were fabricated using three brands: Nacera® Pearl 1, DD cubeX2 and XTCERA TT. A spectrophotometer was used to determine the CIELab values of the specimens, which were placed on a D4-shade resin composite and white acrylic (control) substrates. The ∆E was calculated and compared with the acceptable (AT = 5.5) and perceptible (PT = 2.6) tolerance thresholds. Further investigation was conducted on 72-disc specimens from the monolithic zirconia brand with the best masking ability on D3-shade resin composite and semi-precious alloy. Using two-way ANOVA, the interaction of thickness, brand, and abutment substrate on ∆E was investigated. Nacera® Pearl 1 at 1.5 mm thickness was sufficient to achieve AT on a D4-shade resin composite substrate, whereas 2.0 mm of DD cubeX2 and XTCERA TT were required. Nacera® Pearl 1 further testing on two other substrates requires thicknesses of 1.5 mm and 1.0 mm, respectively. Only the Nacera® Pearl 1 group achieved PT on D3- and D4-shade resin composite (2.0 mm) and semi-precious alloy substrates (1.5 mm). Brand, thickness, and abutment substrate influenced the ∆E (p < 0.001). To achieve an acceptable masking ability, the minimum thickness of monolithic zirconia tested on D3- and D4-shade resin composite and semi-precious alloy should be around 1.5 mm to 2.0 mm.

Background: There has been increasing evidence showing that stingless bee honey exhibits anti-oxidant, anti-inflammatory and anti-cancer properties. Pharmacologically-active components in honey such as flavonoids and phenolic constituents are known to contribute to its medicinal benefits. To the best of our knowledge, this is the first study on evaluating anticancer effects of locally-produced Malaysian stingless bee honey from Heterotrigona itama sp. on malignant glioma cells. Methods: Proliferation and apoptosis studies of U-87 MG cells following stingless bee honey treatment were carried out using MTS assay and acridine orange/propidium iodide dual staining, respectively. Results: Results demonstrated time and dose-dependent cytotoxicity using 0.625%, 1.25% and 10% stingless bee honey (P < 0.05). IC50 values were calculated using cells treated with 10% stingless bee honey. It was also observed that 10% stingless bee honey induced nuclear shrinkage, chromatin condensation and nucleus fragmentation, indicating that cellular changes were consistent with the apoptotic characteristics of the cells. Conclusion: These data provide a good basis for further evaluation of the medicinal properties of stingless bee honey from Heterotrigona itama sp. This source of honey may serve as a potential therapy for malignant glioma.